ImmunityBio, Inc.
About ImmunityBio, Inc.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $113.3M
- Net income
- -$351.4M
- Total assets
- $501.9M
- Market cap
- $7.2B
- Gross margin
- 99.3%
- Operating margin
- -226.0%
- Net margin
- -310.2%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $113.3M
- Cost of revenue
- $753.0K
- Gross profit
- $112.5M
- Operating expenses
- $368.6M
- Operating income
- -$256.0M
- Income tax
- -$135.0K
- Net income
- -$351.5M
- EPS (basic)
- $-0.38
- EPS (diluted)
- $-0.38
Balance sheet
- Total assets
- $501.9M
- Current assets
- $314.9M
- Total liabilities
- $1.0B
- Current liabilities
- $61.8M
- Shareholders’ equity
- -$499.6M
Cash flow
- Operating cash flow
- -$304.9M
- Investing cash flow
- -$149.8M
- Financing cash flow
- $400.2M
- Net cash flow
- -$54.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $7.2B
- EPS (diluted)
- $-0.38
- Shares outstanding
- 1.0B
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 10, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $351.4M in FY2025.
- Revenue grew 12029% from FY2021 to FY2025.
- Gross margin of 99.3%, net margin -310.2%.
- Trading 38% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review ImmunityBio, Inc..
Write a review
News about ImmunityBio, Inc.
News & sentiment via Polygon.io
